Cargando…

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

BACKGROUND: Various treatment combinations of peginterferon (PEG‐IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear. AIMS: To study whether PEG‐IFN add‐on increases response compared to entecavir (ETV) monotherapy, and whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liem, Kin Seng, van Campenhout, Margo J. H., Xie, Qing, Brouwer, Willem Pieter, Chi, Heng, Qi, Xun, Chen, Liang, Tabak, Fehmi, Hansen, Bettina E., Janssen, Harry L. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Hepb Sag and Hbv DNA Predict Response to Pegylated Interferon plus Entecavir
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590282/ https://www.ncbi.nlm.nih.gov/pubmed/30689258 http://dx.doi.org/10.1111/apt.15098

Ejemplares similares

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss
por: Brakenhoff, Sylvia M., et al.
Publicado: (2020)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Fulminant hepatitis
por: Sinclair, Stephen, et al.
Publicado: (1990)

Effects of Entecavir on Hepatitis B Virus Covalently Closed Circular DNA in Hepatitis B e Antigen-Positive Patients with Hepatitis B
por: Shi, Ming, et al.
Publicado: (2015)

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study
por: Lampertico, Pietro, et al.
Publicado: (2020)

Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients
por: Lee, Jeong Guil, et al.
Publicado: (2013)

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Significance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients
por: Mut Surmeli, Deniz, et al.
Publicado: (2021)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
por: Broquetas, Teresa, et al.
Publicado: (2020)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
por: Jun, Dae Won, et al.
Publicado: (2018)

Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy
por: Zhang, Xia-Xia, et al.
Publicado: (2016)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
por: Li, Ming-Hui, et al.
Publicado: (2017)

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
por: Lee, Han Ah, et al.
Publicado: (2016)

Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy
por: Lin, Tien-Ching, et al.
Publicado: (2018)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
por: Yoshida, Kanako, et al.
Publicado: (2021)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Severe Acute Hepatitis B Treated With Entecavir.
por: De Socio, Giuseppe Vittorio Luigi, et al.
Publicado: (2011)

Correlation Between Quantitative Hepatitis B Surface Antigen and Hepatitis B Virus Deoxyribonucleic Acid Levels in Hepatitis B e Antigen-Positive and Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
por: Nirmala, Viva Finhar Insani, et al.
Publicado: (2023)

Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion
por: Yang, Hui Y, et al.
Publicado: (2014)

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
por: Hosaka, Tetsuya, et al.
Publicado: (2021)

Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients
por: Yu, Xiao-qi, et al.
Publicado: (2020)

Interrelationships of Interferon and Immunity During Viral Infections
por: Glasgow, Lowell A.
Publicado: (1970)

The Defensive Role of the Interferon System
por: Baron, Samuel
Publicado: (1970)

Interferon and Interferon Inducers in the Treatment of Malignancies
por: Levy, Hilton B., et al.
Publicado: (1970)

Interferon and Ocular Viral Disease
por: Galin, Miles A., et al.
Publicado: (1970)

Interferon and Interferon Inducers in Protozoal Infections
por: Jahiel, Rene I.
Publicado: (1970)

Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response
por: Cho, Ju-Yeon, et al.
Publicado: (2017)

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
por: Ogawa, Eiichi, et al.
Publicado: (2022)

Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B
por: Perrillo, Robert, et al.
Publicado: (2013)

Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis
por: Sonneveld, Milan J., et al.
Publicado: (2020)

High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B
por: Li, Ming-Hui, et al.
Publicado: (2018)

Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
por: Yim, Sun Young, et al.
Publicado: (2017)

Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B
por: Chi, Xiu-Mei, et al.
Publicado: (2021)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
por: Osborn, Melissa
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hkltdsm15snih96kots8ieuc59